Lead Product(s) : Squalamine phosphate
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Enterin’s oral lead compound, ENT-01 which prevents alpha synuclein from accumulating and aggregating within the enteric nervous system, receives FDA acceptance of an investigator sponsored IND application to treat a patient with prodromal multisystem ...
Brand Name : ENT-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 31, 2023
Lead Product(s) : Squalamine phosphate
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?